Targeted therapy for thyroid cancer
Targeted therapy uses drugs to target specific molecules (such as proteins) on cancer cells or inside them. These molecules help send signals that tell cells to grow or divide. By targeting these molecules, the drugs stop the growth and spread of cancer cells and limit harm to normal cells. Targeted therapy may also be called molecular targeted therapy.
Targeted therapy is sometimes used to treat thyroid cancer. If you have targeted therapy, your healthcare team will use what they know about the cancer and about your health to plan the drugs, doses and schedules.
You may have targeted therapy to:
- treat some types of locally advanced or metastatic thyroid cancer
- treat thyroid cancer that doesn't respond to other treatments or comes back (recurs) after treatment
- relieve pain or control symptoms of advanced thyroid cancer (called palliative therapy)
Types of targeted therapy for thyroid cancer @(Model.HeadingTag)>
The following types of targeted therapy may be used to treat thyroid cancer.
Multikinase inhibitors @(Model.HeadingTag)>
Kinases are proteins on the surface of cells that send signals to help cells grow and form new blood vessels. Multikinase inhibitors block the action of different kinases, which helps slow or stop cancer cells from growing or spreading. Multikinase inhibitors are often given daily as a pill by mouth (orally). They are usually given until the disease progresses or the side effects outweigh the benefits of having the treatment.
Sorafenib (Nexavar) or lenvatinib (Lenvima) may be used to treat papillary or follicular (including Hurhtle cell) thyroid cancer.
Vandetanib (Caprelsa) or cabozantinib (Cabometyx) may be used to treat medullary thyroid cancer.
RET inhibitors @(Model.HeadingTag)>
Some thyroid cancers, such as papillary and follicular, have certain changes in the RET gene. These changes cause the cancer cells to make excess RET kinase protein, which helps them grow. RET inhibitors work by attacking the RET protein. RET inhibitors are often taken by mouth.
RET inhibitors used to treat thyroid cancer include:
- selpercatinib (Retevmo) for medullary, anaplastic or advanced papillary or follicular thyroid cancers that have mutations of the RET gene
- pralsetinib (Gavreto) for medullary thyroid cancer
NTRK inhibitors @(Model.HeadingTag)>
Some thyroid cancers have mutations in the NTRK genes that help cancer cells grow. NTRK inhibitors work to target and disable abnormal proteins made by NTRK genes. NTRK inhibitors are taken by mouth.
NTRK inhibitors used for anaplastic, papillary or follicular thyroid cancer include:
- larotrectinib (Vitrakvi)
- entrectinib (Rozlytrek)
BRAF and MEK inhibitors @(Model.HeadingTag)>
Some anaplastic thyroid cancers have changes in the BRAF gene. The MEK gene works together with the BRAF gene so drugs that block MEK can also help treat cancers with changes in the BRAF gene.
BRAF and MEK inhibitors used to treat thyroid cancer include:
- dabrafenib (Tafinlar)
- trametinib (Mekinist)
Side effects of targeted therapy @(Model.HeadingTag)>
Side effects of targeted therapy will depend mainly on the type of drug or combination of drugs, the dose, how it's given and your overall health. Tell your healthcare team if you have side effects that you think are from targeted therapy. The sooner you tell them of any problems, the sooner they can suggest ways to help you deal with them. Talk to your doctor or pharmacist about what side effects to expect.
Multikinase inhibitors can cause fatigue, skin rash, loss of appetite, diarrhea, nausea and high blood pressure. They can also cause pain, tingling, numbness, redness and scaling or shedding of skin on the hands and feet (called hand-foot syndrome).
RET inhibitors can cause dry mouth, diarrhea, constipation, high blood pressure, fatigue, swelling in the hands or feet, skin rash, high blood sugar levels, low white blood cell count and low blood platelets.
NTRK inhibitors can cause dizziness, fatigue, nausea, vomiting, constipation, weight gain and diarrhea.
BRAF and MEK inhibitors can cause skin changes, rash, itching, sun sensitivity, headache, fever, chills, joint or muscle pain, fatigue, cough, hair loss, nausea, diarrhea and high blood pressure.
Find out more about targeted therapy @(Model.HeadingTag)>
Shereen Ezzat, MD, FRCPC, FACP
Bible KC, Kebebebew E, Brierley J, Brito JP, Cabanillas ME et al . 2021 American Thyroid Association guidelines for management of patients with anaplastic thryoid cancer . Thyroid . 2021 : 31(3): 337–386 .
American Cancer Society. Treating Thyroid Cancer . 2021: https://www.cancer.org/.
HealthLinkBC. Thyroid Cancer. 2019: https://www.healthlinkbc.ca/.
Alberta Health Services. Thyroid Cancer Treatment in Alberta. Edmonton: 2019: https://www.albertahealthservices.ca/.
Sharma PK. Medscape Reference: Thyroid Cancer. WebMD LLC; 2021: https://www.medscape.com/.
Alberta Health Services. MyHealth Alberta.ca: Thyroid Cancer. Government of Alberta; https://myhealth.alberta.ca/.
Cancer Care Ontario. Drug Monograph: Sorafenib. 2015: https://www.cancercare.on.ca/cms/One.aspx?portalId=1377&pageId=10760.
Cancer Care Ontario. Drug Monograph: Vandetanib. 2014: https://www.cancercare.on.ca/cms/One.aspx?portalId=1377&pageId=10760.
Eli Lilly Canada Inc.. Product Monograph Selpercatinib (Retevmo). June 11, 2021: http://pi.lilly.com/ca/retevmo-ca-pm.pdf. Thursday, September 16, 2021.
Hoffmann-La Roch Limited. Product monograph Pralsetinib (Gavreto ). July 12, 2021: https://www.rochecanada.com/content/dam/rochexx/roche-ca/products/ConsumerInformation/MonographsandPublicAdvisories/gavreto/GAVRETO_PM_CIE.pdf. Thursday, September 16, 2021.
Cancer Care Ontario. Drug Monograph: Dabrafenib. 2016: https://www.cancercare.on.ca/toolbox/drugformulary/.
Janssen Inc. Product Monograph: Cabometyx. https://ipsen.com/websites/IPSENCOM-PROD/wp-content/uploads/sites/18/2020/05/14140500/Cabometyx-PM-EN-7May2020.pdf.
Eisai Limited. Product Monograph: Lenvima. https://pdf.hres.ca/dpd_pm/00048812.PDF.
Novartis Pharmaceuticals Canada Inc. Product Monograph: Mekinst. https://www.novartis.ca/sites/www.novartis.ca/files/mekinist_scrip_e.pdf.
Hoffmann-La Roche Limited. Product Monograph: Rozlytrek. https://www.rochecanada.com/content/dam/rochexx/roche-ca/products/ConsumerInformation/MonographsandPublicAdvisories/Rozlytrek/Rozlytrek_PM_CIE.pdf.
Novartis Pharmaceuticals Canada Inc. Product Monograph: Tafinlar. https://www.novartis.ca/sites/www.novartis.ca/files/tafinlar_scrip_e.pdf.
Bayer Inc. Product Monograph: Vitrakvi. https://pdf.hres.ca/dpd_pm/00060963.PDF.
PDQ® Adult Treatment Editorial Board. Thyroid Cancer Treatment (PDQ®) – Health Professional Version. Bethesda, MD: National Cancer Institute; 2021: https://www.cancer.gov/.
American Society of Clinical Oncology (ASCO). Cancer.net: Thyroid Cancer. 2021: https://www.cancer.net/.
National Comprehensive Cancer Network. NCCN Guidelines for Patients: Thyroid Cancer. 2020.
PDQ® Adult Treatment Editorial Board. Thyroid Cancer Treatment (PDQ®) – Patient Version. Bethesda, MD: National Cancer Institute; 2021: https://www.cancer.gov/.
National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma (Version 3.2021) . 2021 .
Kotwal A, Davidge-Pitts CJ, Thompson GB. Thyroid Tumors. DeVita VT Jr., Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 11th ed. Philadelphia, PA: Wolters Kluwer; 2019: 81:1326–1337.